Details for New Drug Application (NDA): 206693
✉ Email this page to a colleague
The generic ingredient in TADALAFIL is tadalafil. There are twenty-five drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the tadalafil profile page.
Summary for 206693
Tradename: | TADALAFIL |
Applicant: | Zydus Pharms |
Ingredient: | tadalafil |
Patents: | 0 |
Pharmacology for NDA: 206693
Mechanism of Action | Phosphodiesterase 5 Inhibitors |
Medical Subject Heading (MeSH) Categories for 206693
Suppliers and Packaging for NDA: 206693
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
TADALAFIL | tadalafil | TABLET;ORAL | 206693 | ANDA | Northwind Pharmaceuticals, LLC | 51655-063 | 51655-063-54 | 15 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (51655-063-54) |
TADALAFIL | tadalafil | TABLET;ORAL | 206693 | ANDA | Northwind Pharmaceuticals, LLC | 51655-063 | 51655-063-87 | 6 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (51655-063-87) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 2.5MG | ||||
Approval Date: | Mar 26, 2019 | TE: | AB1 | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
Approval Date: | Mar 26, 2019 | TE: | AB1 | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
Approval Date: | Mar 26, 2019 | TE: | AB1 | RLD: | No |
Complete Access Available with Subscription